Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jul;26(7):1295-1304.
doi: 10.1111/1756-185X.14719. Epub 2023 Apr 28.

Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta-analysis

Young Ho Lee  1 , Gwan Gyu Song  1
Affiliations
Meta-Analysis

Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta-analysis

Young Ho Lee et al. Int J Rheum Dis. 2023 Jul.

Abstract

Objectives: This study aimed to investigate the association between functional Fc gamma receptor 3A (FCGR3A) V158F and FCGR2A R131H polymorphisms and biologic therapy in rheumatoid arthritis (RA) patients.

Methods: We searched Medline, Embase, and Cochran databases for available articles. This study is a meta-analysis of the association between the FCGR3A V158F and FCGR2A R131H polymorphisms and their responsiveness to biologics in RA patients.

Results: Seventeen studies involving RA patients with FCGR3A V158F (n = 1884) and FCGR2A R131H (n = 1118) polymorphisms were considered. This meta-analysis showed that the FCGR3A V allele was associated with responsiveness to rituximab (odds ratio [OR] = 1.431, 95% CI = 1.081-1.894, P = 0.012), but not with tumor necrosis factor (TNF) blockers, tocilizumab, or abatacept. A significant association was also found between the FCGR3A V158F polymorphism and responsiveness to biologics using the dominant-recessive model. Additionally, the FCGR3A V158F polymorphism was associated with responsiveness to TNF blockers in the homozygous contrast model. Meta-analysis revealed an association between the FCGR2A RR + RH genotype and responsiveness to biologics (OR = 1.385, 95% CI = 1.007-1.904, P = 0.045).

Conclusions: This meta-analysis demonstrates that FCGR3A V allele carriers show better responsiveness to rituximab, and FCGR2A R allele carriers may show a better response to biologics in RA treatment. Genotyping of these polymorphisms could be a useful tool to find associations with the responsiveness of personalized medicine to biologics.

Keywords: FCGR2A; FCGR3A; biologics; polymorphisms; responsiveness; rheumatoid arthritis.

PubMed Disclaimer

References

REFERENCES

    1. Kim H, Sung YK. Epidemiology of rheumatoid arthritis in Korea. J Rheum Dis. 2021;28(2):60-67. doi:10.4078/jrd.2021.28.2.60
    1. Lee YK, Bae SC. Mortality in Korean patients with rheumatoid arthritis. J Rheum Dis. 2021;28(3):113-118. doi:10.4078/jrd.2021.28.3.113
    1. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med. 2000;343(22):1594-1602. doi:10.1056/nejm200011303432202
    1. Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014;73(1):3-5. doi:10.1136/annrheumdis-2013-204317
    1. Kim J, Koh JH, Choi SJ, et al. KOBIO, the first web-based Korean biologics registry operated with a unified platform among distinct disease entities. J Rheum Dis. 2021;28(4):176-182. doi:10.4078/jrd.2021.28.4.176

Publication types

MeSH terms

LinkOut - more resources